menu
    • menu

    Company profile for Entasis Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. Since receiving our initial funding from AstraZeneca, we have raised another $81.9 million gross proceeds from equity financings from a number of U.S.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Entasis TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Boston BioHub 35 Gatehouse Drive Waltham, MA USA 02451
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.entasistx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Entasis Therap’s Nuzolvence Receives Approval in US
    Entasis Therap’s Nuzolvence Receives Approval in US

    12 Dec 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219491

    FDA
    12 Dec 2025
    Share Share
    Entasis lands first antibiotic approval eight years after spinning out of AZ
    Entasis lands first antibiotic approval eight years after spinning out of AZ

    25 May 2023

    // Amber Tong ENDPTS

    https://endpts.com/fda-approves-antibiotic-for-pneumonia-caused-by-hard-to-treat-bacteria/

    Amber Tong ENDPTS
    25 May 2023
    Share Share
    Adcomm unanimously recommends Entasis' bacterial pneumonia candidate for resistant infections
    Adcomm unanimously recommends Entasis' bacterial pneumonia candidate for resistant infections

    17 Apr 2023

    // Paul Schloesser ENDPTS

    https://endpts.com/adcomm-unanimously-recommends-entasis-bacterial-pneumonia-candidate-for-resistant-infections/

    Paul Schloesser ENDPTS
    17 Apr 2023
    Share Share
    Adcomm unanimously recommends Entasis' bacterial pneumonia
    Adcomm unanimously recommends Entasis' bacterial pneumonia

    17 Apr 2023

    // Paul Schloesser ENDPTS

    https://endpts.com/adcomm-unanimously-recommends-entasis-bacterial-pneumonia-candidate-for-resistant-infections/

    Paul Schloesser ENDPTS
    17 Apr 2023
    Share Share
    Entasis Presents Safety Data from Landmark PIII ATTACK Trial at IDWEEK 2022
    Entasis Presents Safety Data from Landmark PIII ATTACK Trial at IDWEEK 2022

    19 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/19/2537378/0/en/Entasis-Therapeutics-a-Wholly-Owned-Subsidiary-of-Innoviva-Presents-Efficacy-and-Safety-Data-from-Landmark-Phase-3-ATTACK-Trial-at-IDWEEK-2022.html

    GLOBENEWSWIRE
    19 Oct 2022
    Share Share
    Entasis , a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR
    Entasis , a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR

    12 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/12/2532897/0/en/Entasis-Therapeutics-a-Wholly-Owned-Subsidiary-of-Innoviva-Announces-Data-on-SUL-DUR-to-be-Presented-at-IDWeek-2022.html

    GLOBENEWSWIRE
    12 Oct 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search